Navigation Links
Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation
Date:11/8/2010

loped a substantial body of data on Epanova, which points to an improved and more predictable bioavailability as compared to the ethyl ester form found in prescription Omega 3 products currently available.  Triglyceride lowering with Epanova was previously observed in two large, placebo-controlled, randomized, double-blind, Phase III studies involving 748 Crohn's Disease patients with normal triglyceride levels for greater than or equal to 52 weeks; approximately 400 of which were treated with Epanova for remission of disease. In all studies performed to date, Epanova has demonstrated a very good safety and tolerability profile.

About Hypertriglyceridemia Hypertriglyceridemia refers to a condition in which patients have high blood levels of triglycerides and is associated with increased risk of heart disease. It is one component of a range of lipid disorders collectively referred to as dyslipidemia. The overall dyslipidemia population in the U.S. is believed to be in excess of 100 million, with over 27 million of those diagnosed with hypertriglyceridemia (TGs greater than 200mg/dL) and an estimated 5 million with very high triglyceride levels (TGs greater than 500mg/dL). Very high triglycerides are associated with an increased risk of pancreatitis. Regulatory approval for the treatment of very high triglycerides is based on a significant reduction in the serum triglyceride levels.

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia.  Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.  The lead product candidate is Epanova, an Omega 3 fatty a
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
2. Biostar Pharmaceuticals, Inc. Expands Rural Network by Over 21% in Third Quarter 2010; Brings Total Number of Locations to 8,500
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
7. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
8. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
10. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
11. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier ... Dr. James L. Sherley, director of the Adult Stem ... on an often overlooked and under appreciated unique property ... Self-Renewal by Distributed Stem Cells: Misunderstood in the Past, ... message to congress participants. He gave the address ...
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ... the housing market remaining soft. , This solid economic news ...
(Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... Inc., a division of GE Industrial Systems, announced ... a Green Bay manufacturing software development company. , ... Execution Systems (MES) technology for the manufacturing of ... as well as for pulp and paper products. ...
... to fighting breast cancer, and GE Medical Systems, headquartered ... AD and Second Look Digital are computer-aided detection (CAD) ... digital mammography system. CADx Systems, Inc. developed the Second ... the review of breast exams. , ,GE is ...
... until he gets to the better drugs, faster part of ... behind the Madison-based companys products is likely to hit the ... age when diseases and treatments become as common in conversation ... and a half-year-old company that Vodenlich joined as president earlier ...
Cached Biology Technology:Green Bay Software Company Purchased by GE 2New Technology in Fight against Breast Cancer 2Chipping Away at Drug Development 2Chipping Away at Drug Development 3
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... the U.S. Department of Energy,s Brookhaven National Laboratory have ... against human adenovirus, a cause of ailments ranging from ... published in FEBS Letters , a journal of ... researchers sifted through thousands of compounds to determine which ...
... from Uppsala University, Sweden, show that the key to ... and Creutzfeldt-Jakob disease may lie in the ribosome, the ... recently published in the Journal of Biological Chemistry ... by misfolding of prion proteins. Examples of prion diseases ...
... that has sickened thousands in Haiti came from a single ... the past three years as some have thought, according to ... open-access journal of the American Society for Microbiology. ... findings that indicate Vibrio cholerae bacteria were introduced ...
Cached Biology News:Scientists identify promising antiviral compounds 2Scientists identify promising antiviral compounds 3The ribosome -- a new target for antiprion medicines 2Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 2Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 3
MAGP-2 (C-19)...
Laminin gamma-2 (G-16)...
... Proliferation Kit, For 100 slides. Immunocytochemistry.Sample ... in vitro tissue labeling.Recommended cell number: ... (labeling 1-2 hours).Store at 2-8 C ... Category: Drug Screening & Cellular Assays, ...
Dysadherin 2 (L-15)...
Biology Products: